S. Baculea

The Burden of Cancer and Market Access for New Oncology Drugs in European Countries

N. Chiriac, C. Vlădescu, S. Baculea, 2009 .

Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease

F. Schain, M. Remberger, J. Mattsson, 2020, The European Journal of Health Economics.

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

J. Diels, S. Van Sanden, S. Côté, 2017, Advances in Therapy.

Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.

K. Fahrbach, J. Diels, Yingxin Xu, 2018, Journal of comparative effectiveness research.

Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy

S. Mealing, S. Côté, S. Baculea, 2017, Journal of medical economics.

Managing Clinical Risk in Romania

C. Ţereanu, S. Baculea, P. Radu, 2008 .